We are live on ! Find out more
EDIT icon

Editas Medicine

195 hedge funds and large institutions have $51M invested in Editas Medicine in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 61 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $668K | Put options by funds: $339K

6% less funds holding

Funds holding: 207195 (-12)

8.81% less ownership

Funds ownership: 61.84%53.03% (-8.8%)

21% less capital invested

Capital invested by funds: $64.8M → $51M (-$13.8M)

28% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 61

32% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 34

Holders
195
Holders Change
-12
Holders Change %
-5.8%
% of All Funds
2.61%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
44
Reduced
61
Closed
34
Calls
$668K
Puts
$339K
Net Calls
+$329K
Net Calls Change
+$321K
Name Holding Trade Value Shares
Change
Change in
Stake
HSBC Holdings
51
HSBC Holdings
United Kingdom
$67.4K -$93 -63 -0.1%
Group One Trading
52
Group One Trading
Illinois
$64.3K -$56.3K -38,249 -41%
Cerity Partners
53
Cerity Partners
New York
$56.9K +$72.2K +49,060 New
PCIA
54
Prime Capital Investment Advisors
Kansas
$55.5K -$2.47K -1,679 -3%
Carson Wealth (CWM LLC)
55
Carson Wealth (CWM LLC)
Nebraska
$55K +$47.7K +32,455 +219%
LPL Financial
56
LPL Financial
California
$53.9K -$10.1K -6,842 -13%
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$52.9K -$145K -98,422 -68%
Wealth Enhancement Advisory Services
58
Wealth Enhancement Advisory Services
Minnesota
$52.2K +$39.1K +26,601 +144%
SOW
59
State of Wyoming
Wyoming
$51.5K +$65.3K +44,358 New
T. Rowe Price Associates
60
T. Rowe Price Associates
Maryland
$51K
JG
61
Jain Global
New York
$48.9K -$92.1K -62,630 -60%
CF
62
Corebridge Financial
Texas
$47.1K -$884 -601 -1%
BAM
63
Brave Asset Management
New Jersey
$40.6K +$36.8K +25,000 +250%
SCM
64
SCS Capital Management
Massachusetts
$40.6K +$51.5K +35,000 New
Allspring Global Investments
65
Allspring Global Investments
North Carolina
$40.4K +$16.6K +11,252 +46%
MML Investors Services
66
MML Investors Services
Massachusetts
$40K +$26.6K +18,106 +108%
B
67
Bailard
California
$39.3K
Manulife (Manufacturers Life Insurance)
68
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$39.1K +$984 +669 +2%
TWM
69
Thrive Wealth Management
Pennsylvania
$38.9K +$7.36K +5,000 +18%
SG Americas Securities
70
SG Americas Securities
New York
$37K -$73.8K -50,153 -61%
HKAM
71
Horizon Kinetics Asset Management
New York
$36.8K
Fidelity Investments
72
Fidelity Investments
Massachusetts
$36.7K -$285K -193,987 -86%
Baird Financial Group
73
Baird Financial Group
Wisconsin
$35.7K
DIM
74
DLK Investment Management
California
$35.6K +$7.36K +5,000 +19%
VPIM
75
Vanguard Personalized Indexing Management
California
$30.9K +$23.6K +16,032 +152%

EDIT Hedge Fund Activity: Q1 2025 in Review

195 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2025, worth a combined $51M — down 21% from $64.8M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of EDIT and 23 opened new positions — a net loss of 11 holders — while 61 trimmed existing stakes and 44 added.

The largest buyer was UBS AM, adding an estimated $2.1M. The largest seller was Millennium Management, cutting an estimated $3.62M.

  • 195 institutional investors held Editas Medicine (EDIT) as of Q1 2025, down from 207 in Q4 2024.
  • Funds reported $51M of Editas Medicine stock for Q1 2025, down 21% quarter-over-quarter.
  • 23 funds opened new Editas Medicine positions in Q1 2025 and 34 closed out, a net change of -11 holders.
  • The largest Editas Medicine buyer in Q1 2025 was UBS AM, an estimated $2.1M added.
  • The largest Editas Medicine seller in Q1 2025 was Millennium Management, an estimated $3.62M sold.

Based on aggregated 13F filings for Q1 2025.